Literature DB >> 32704608

Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.

Elizabeth K Lee1, Katharine M Esselen2, David L Kolin3, Larissa J Lee4, Ursula A Matulonis1, Panagiotis A Konstantinopoulos1.   

Abstract

Entities:  

Year:  2020        PMID： 32704608      PMCID： PMC7377332          DOI： 10.1200/PO.20.00063

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  39 in total

1.  Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis.

Authors:  Dimitrios Nasioudis; Eloise Chapman-Davis; Melissa K Frey; Thomas A Caputo; Steven S Witkin; Kevin Holcomb
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

2.  The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Authors:  Yemin Wang; Shary Yuting Chen; Anthony N Karnezis; Shane Colborne; Nancy Dos Santos; Jessica D Lang; William Pd Hendricks; Krystal A Orlando; Damian Yap; Friedrich Kommoss; Marcel B Bally; Gregg B Morin; Jeffrey M Trent; Bernard E Weissman; David G Huntsman
Journal:  J Pathol       Date:  2017-06-02       Impact factor: 7.996

3.  The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Authors:  David A Schaer; Richard P Beckmann; Jack A Dempsey; Lysiane Huber; Amelie Forest; Nelusha Amaladas; Yanxia Li; Ying Cindy Wang; Erik R Rasmussen; Darin Chin; Andrew Capen; Carmine Carpenito; Kirk A Staschke; Linda A Chung; Lacey M Litchfield; Farhana F Merzoug; Xueqian Gong; Philip W Iversen; Sean Buchanan; Alfonso de Dios; Ruslan D Novosiadly; Michael Kalos
Journal:  Cell Rep       Date:  2018-03-13       Impact factor: 9.423

4.  Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary.

Authors:  Omer Jamy; George Yaghmour; Felicia Hare; Michael G Martin
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

5.  Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.

Authors:  P Pautier; V Ribrag; P Duvillard; A Rey; I Elghissassi; I Sillet-Bach; P Kerbrat; F Mayer; A Lesoin; B Brun; H Crouet; J C Barats; P Morice; C Lhommé
Journal:  Ann Oncol       Date:  2007-08-30       Impact factor: 32.976

6.  Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.

Authors:  D Callegaro-Filho; D M Gershenson; A M Nick; M F Munsell; P T Ramirez; P J Eifel; E D Euscher; R M Marques; S M Nicolau; K M Schmeler
Journal:  Gynecol Oncol       Date:  2015-11-04       Impact factor: 5.482

7.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Authors:  Wanqiang Sheng; Martin W LaFleur; Thao H Nguyen; Sujun Chen; Ankur Chakravarthy; Jake Ryan Conway; Ying Li; Hao Chen; Henry Yang; Pang-Hung Hsu; Eliezer M Van Allen; Gordon J Freeman; Daniel D De Carvalho; Housheng Hansen He; Arlene H Sharpe; Yang Shi
Journal:  Cell       Date:  2018-06-21       Impact factor: 41.582

8.  Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.

Authors:  Ye Qin; Shauna N Vasilatos; Lin Chen; Hao Wu; Zhishen Cao; Yumei Fu; Min Huang; Anda M Vlad; Binfeng Lu; Steffi Oesterreich; Nancy E Davidson; Yi Huang
Journal:  Oncogene       Date:  2018-08-15       Impact factor: 9.867

9.  SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.

Authors:  Yibo Xue; Brian Meehan; Zheng Fu; Xue Qing D Wang; Pierre Olivier Fiset; Ralf Rieker; Cameron Levins; Tim Kong; Xianbing Zhu; Geneviève Morin; Lashanda Skerritt; Esther Herpel; Sriram Venneti; Daniel Martinez; Alexander R Judkins; Sungmi Jung; Sophie Camilleri-Broet; Anne V Gonzalez; Marie-Christine Guiot; William W Lockwood; Jonathan D Spicer; Abbas Agaimy; William A Pastor; Josée Dostie; Janusz Rak; William D Foulkes; Sidong Huang
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919

Review 10.  An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings.

Authors:  Bingjian Lu; Haiyan Shi
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207
View more
  2 in total

1.  Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Authors:  Guiling Li; Yao Jiang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

2.  Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.

Authors:  Nina Anžič; Fatime Krasniqi; Anna-Lena Eberhardt; Alexandar Tzankov; Jasmin Dionne Haslbauer
Journal:  Case Rep Oncol       Date:  2021-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.